Cargando…

Updated insights on dementia‐related risk of sacubitril/valsartan: A real‐world pharmacovigilance analysis

AIM: Sacubitril/valsartan is a new cardiovascular agent characterized by its dual inhibition on the reninangiotensin system (RAS) and the neprilysin. As neprilysin also involved itself in the degradation of amyloid‐β, there is an ongoing concern about the effect of sacubitril/valsartan on cognition,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Congqin, Ding, Lingqing, Fu, Fang, Xiao, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401082/ https://www.ncbi.nlm.nih.gov/pubmed/36971193 http://dx.doi.org/10.1111/cns.14195

Ejemplares similares

The history and mystery of sacubitril/valsartan: From clinical trial to the real world
por: Zhang, Mingsong, et al.
Publicado: (2023)

Insights into implementation of sacubitril/valsartan into clinical practice
por: Martens, Pieter, et al.
Publicado: (2018)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study
por: Wang, Chen, et al.
Publicado: (2023)

Real-world evidence of autoimmune hepatitis following COVID-19 vaccination: A population-based pharmacovigilance analysis
por: Chen, Congqin, et al.
Publicado: (2023)

Real‐world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany
por: Wachter, Rolf, et al.
Publicado: (2019)

Real-World Usage of Sacubitril/Valsartan in Korea: A Multi-Center, Retrospective Study
por: Park, Jin Joo, et al.
Publicado: (2022)

Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
por: Nordberg Backelin, Charlotte, et al.
Publicado: (2020)

Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real‐world study in Taiwan
por: Chang, Po‐Cheng, et al.
Publicado: (2020)

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF
por: Visco, Valeria, et al.
Publicado: (2022)

Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Disease—A Real-World Experience
por: Pereira, Sara C., et al.
Publicado: (2023)

Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)
por: Di Lenarda, Andrea, et al.
Publicado: (2023)

Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system
por: Chen, Congqin, et al.
Publicado: (2022)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
por: Polito, Maria Vincenza, et al.
Publicado: (2020)

Initial Real-World Practical Experience of Sacubitril/Valsartan Treatment in Japanese Patients With Chronic Heart Failure
por: Nakamura, Makiko, et al.
Publicado: (2021)

Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real‐world study
por: Chen, Wenwen, et al.
Publicado: (2021)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
por: Ding, Ying, et al.
Publicado: (2023)

Canadian Real-World Experience of Using Sacubitril/Valsartan in Patients With Heart Failure With Reduced Ejection Fraction: Insight From the PARASAIL Study
por: Haddad, Haissam, et al.
Publicado: (2020)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Re: Implication of low‐dose sacubitril/valsartan
por: Pandey, Amitabh C., et al.
Publicado: (2021)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022)

Sacubitril/Valsartan in the Treatment of Right Ventricular Dysfunction in Patients With Heart Failure With Reduced Ejection Fraction: A Real-world Study
por: Yang, Ying, et al.
Publicado: (2022)

Eligibility of sacubitril–valsartan in a real‐world heart failure population: a community‐based single‐centre study
por: Norberg, Helena, et al.
Publicado: (2018)

“Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
por: Simpson, Joanne, et al.
Publicado: (2019)

Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study
por: Ganesananthan, Sashiananthan, et al.
Publicado: (2020)

Real-World Safety of Sacubitril/Valsartan in Women and Men With Heart Failure and Reduced Ejection Fraction: A Meta-analysis
por: Nuechterlein, Kaitlin, et al.
Publicado: (2021)

Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients
por: Wang, Bin, et al.
Publicado: (2022)

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension
por: Chen, Jianshu, et al.
Publicado: (2023)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
por: Anderson, Sarah L, et al.
Publicado: (2018)

The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant
por: Beck-da-Silva, Luís, et al.
Publicado: (2019)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
por: Andersen, Ulrik Ø, et al.
Publicado: (2020)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
por: Vergaro, Giuseppe, et al.
Publicado: (2020)

Sacubitril/valsartan in the treatment of systemic right ventricular failure
por: Zandstra, Tjitske E, et al.
Publicado: (2021)

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

A narrative review on sacubitril/valsartan and ventricular arrhythmias
por: Wei, Zhaoyang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pcbggkpdec0kf7pahpt9qs4esr